Skip to main content

Table 5 Mean of haematological and biochemical parameters of G6PD (genotypes A) deficient and non-deficient (genotype B) subjects taking primaquine for 3 and 7 days

From: G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

 

Day 1: mean (SD) (n)a

Day 3: mean (SD) (n)

Day 7: mean (SD) (n)

A− (males)

A

B

A− (males)

A

B

A− (males)

A

B

RBC × 106/µL

4.03 (0.42) (5)

4.1 (0.7) (7)

4.4 (0.5) (48)

3.7 (0.5) (5)

3.6 (0.7) (7)

4.1 (0.6) (48)

3.7 (0.3) (5)

3.9 (0.5) (6)

4.2 (0.5) (46)

Haemoglobin g/dL

11.3 (1.71) (5)

11.6 (2.0) (7)

12.4 (1.7) (48)

10.0 (1.3) (5)

10.2 (1.9) (7)

11.8 (1.7) (48)

9.9 (1.6) (5)

10.7 (1.9) (6)

12.1 (1.4) (46)

Hematocrit %

34.5 (5.05) (5)

35.4 (6.2) (7)

37.5 (5.0) (48)

30.4 (3.2) (5)

30.9 (5.4) (7)

36 (4.7) (48)

29.4 (4.7) (5)

32.1 (6.6) (6)

36.8 (4) (46)

Reticulocyte %

1.1 (0.5) (3)

1.1 (0.5) (4)

2. 2 (1.8) (41)

2.4 (1.3) (3)

2.2 (1.2) (4)

2.6 (1.9) (41)

11.2 (9.5) (3)

11.2 (9.5) (3)

3.6 (2.9) (40)

AST IU/L

30.1 (24.2) (3)

29.2 (19.8) (4)

34.6 (19.7) (41)

35.3 (7.2) (3)

32.6 (7.9) (4)

31.8 (21.5) (41)

39.0 (33.9) (3)

39.0 (33.9) (3)

36.9 (25.4) (40)

ALT IU/L

33.6 (33.1) (3)

30.3 (27.8) (4)

37.2 (24.9) (41)

29.4 (17) (3)

27.1 (14.6) (4)

37.2 (31) (41)

120.2 (113) (3)

120.2 (113) (3)

52.3 (48.3) (40)

Total bilirubin mg/dL

1.2 (0.6) (3)

1.1 (0.6) (4)

1.4 (0.8) (41)

2.0 (1.1) (3)

1.8 (1.0) (4)

0.9 (0.4) (41)

0.6 (0.2) (3)

0.6 (0.2) (3)

0.7 (0.31) (40)

Direct bilirubin mg/dL

0.8 (0.6) (3)

0.7 (0.5) (4)

0.9 (0.7) (41)

1.1 (0.7) (3)

0.9 (0.7) (4)

0.6 (0.3) (41)

0.3 (0.1) (3)

0.3 (0.1) (3)

0.5 (0.2) (40)

Indirect bilirubin mg/dL

0.4 (0.2) (3)

0.4 (0.2) (4)

0.6 (0.4) (41)

0.9 (0.7) (3)

0.9 (0.6) (4)

0.4 (0.3) (41)

0.3 (0.1) (3)

0.3 (0.1) (3)

0.3 (0.2) (40)

Creatinin mg/dL

1.0 (0.2) (3)

1.0 (0.13) (4)

0.9 (0.1) (41)

0.9 (0) (3)

0.9 (0) (4)

0.8 (0.1) (41)

0.9 (0.1) (3)

0.9 (0.1) (3)

0.8 (0.2) (40)

  1. aBefore primaquine treatment